Robert W. Baird restated their buy rating on shares of Hologic (NASDAQ:HOLX) in a research report sent to investors on Monday, Benzinga reports.
A number of other equities research analysts also recently weighed in on HOLX. Morgan Stanley upped their target price on Hologic from $80.00 to $84.00 and gave the stock an equal weight rating in a research report on Tuesday, December 15th. Zacks Investment Research upgraded Hologic from a hold rating to a buy rating and set a $72.00 price objective for the company in a research report on Monday, November 2nd. BTIG Research increased their price objective on Hologic from $84.00 to $91.00 and gave the company a buy rating in a research report on Monday. Smith Barney Citigroup increased their price objective on Hologic from $90.00 to $85.00 in a research report on Thursday, November 5th. Finally, JPMorgan Chase & Co. increased their price objective on Hologic from $75.00 to $85.00 and gave the company an overweight rating in a research report on Thursday, November 5th. Five equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The stock presently has an average rating of Buy and an average price target of $81.00.
HOLX opened at $74.57 on Monday. The company has a market capitalization of $19.21 billion, a price-to-earnings ratio of 17.75, a price-to-earnings-growth ratio of 0.62 and a beta of 1.27. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.79 and a quick ratio of 1.47. Hologic has a 1-year low of $26.49 and a 1-year high of $85.00. The business has a 50 day moving average price of $78.89 and a two-hundred day moving average price of $70.84.
Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, January 27th. The medical equipment provider reported $2.86 earnings per share for the quarter, topping analysts’ consensus estimates of $2.14 by $0.72. The firm had revenue of $1.61 billion during the quarter, compared to the consensus estimate of $1.39 billion. Hologic had a return on equity of 45.24% and a net margin of 29.53%. The firm’s revenue for the quarter was up 89.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.61 earnings per share. Equities analysts expect that Hologic will post 7.17 EPS for the current fiscal year.
In other news, insider Kevin R. Thornal sold 16,869 shares of the company’s stock in a transaction on Thursday, December 10th. The shares were sold at an average price of $73.99, for a total value of $1,248,137.31. Following the transaction, the insider now directly owns 40,849 shares of the company’s stock, valued at $3,022,417.51. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Benjamin Jordan Cohn sold 8,396 shares of the company’s stock in a transaction on Thursday, February 4th. The stock was sold at an average price of $84.31, for a total transaction of $707,866.76. The disclosure for this sale can be found here. 1.00% of the stock is owned by insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of HOLX. Ellevest Inc. increased its stake in shares of Hologic by 93.4% in the third quarter. Ellevest Inc. now owns 1,441 shares of the medical equipment provider’s stock worth $96,000 after acquiring an additional 696 shares during the last quarter. Bradley Foster & Sargent Inc. CT acquired a new position in shares of Hologic in the third quarter worth $1,564,000. Meritage Portfolio Management acquired a new position in shares of Hologic in the third quarter worth $6,486,000. Xponance Inc. increased its position in Hologic by 0.6% during the third quarter. Xponance Inc. now owns 29,189 shares of the medical equipment provider’s stock worth $1,940,000 after buying an additional 178 shares during the last quarter. Finally, State of Michigan Retirement System increased its position in Hologic by 0.3% during the third quarter. State of Michigan Retirement System now owns 66,120 shares of the medical equipment provider’s stock worth $4,395,000 after buying an additional 200 shares during the last quarter. 92.43% of the stock is currently owned by institutional investors and hedge funds.
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.
See Also: Oversold
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.